CUO - Controversies in Urologic Oncology

Friday, March 29 - Workshops                    --- approved with 6 DFP points ---

• 12:30 - 13:00   Registration
• 13:00 - 17:30   Workshops
• 18:30 - 21:30   Trainee & Early-Career Networking Dinner

Saturday, March 30 - Scientific Meeting   --- approved with 10 DFP points ---

• 08:00-17:00 CUO Symposium

Join this annual meeting under the auspices of        

• Central European Urological Society (CEUS)
• Austrian-Polish Friends of Urology (FOU)
• Working Groups of the Austrian Urological Society (ÖGU):
  Imaging, Laparoscopic/Robotic, Endourology and Urolithiasis, Oncology, Pediatric Urology and Young Urology
• Comprehensive Cancer Center and the
• Department of Urology at the Medical University of Vienna

SPONSORS AND PARTNERS

OVERVIEW

This annual, multidisciplinary, one-day conference will provide an update on the clinical management of patients with prostate, kidney and bladder (urothelial) cancers.  Didactic lectures will present the many recent advances in the treatment of these diseases and their integration into the multidisciplinary management of patients with early stage, high risk, and metastatic disease. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them. Interactive discussions with experts in the field will enhance the learning experience

The Congress will focus on key clinical topics in the management of prostate, kidney and bladder malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as explore emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. The Congress continues to evolve and expand its coverage of some of the fastest moving areas in the management of genitourinary malignancies. To that end, there will be an expanded focus on prostate cancer, bladder cancer and renal cell carcinoma, given recent practice-changing developments that continue to alter the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of emerging biomarkers for these tumors, will be answered during expanded sessions on these topics.

This year’s Controversies in Urologic Oncology congress is not to be missed! The activity is sure to continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with these malignancies.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with prostate, kidney and bladder malignancies. Urologists, fellows, nurses, physician assistants, pharmacists, researchers, radiologists, nuclear medicine physicians, and other healthcare professionals interested in the treatment of prostate, kidney and bladder cancers may also participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

• Describe methods to stratify risk and tumor information that can provide the rationale for clinical decision making in the management of prostate, kidney and bladder cancers
• Summarize recommendations that shape current strategies to care for patients with prostate, kidney and bladder cancers
• Develop multidisciplinary strategies to optimize outcomes by proactive mitigation of known treatment-related side effects in caring for patients with prostate, kidney and bladder cancers
• Assess recent practice-changing clinical trial findings concerning novel compounds or strategies to manage prostate, kidney and bladder cancers
• Apply emerging clinical concepts to support the management of prostate, kidney and bladder cancers in consideration of evolving treatment paradigms in the field